Q1 2024 Earnings Estimate for Henry Schein, Inc. Issued By Zacks Research (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research lowered their Q1 2024 EPS estimates for Henry Schein in a research report issued to clients and investors on Wednesday, May 1st. Zacks Research analyst U. Biswas now forecasts that the company will post earnings per share of $0.99 for the quarter, down from their previous estimate of $1.00. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2024 earnings at $1.42 EPS, FY2024 earnings at $5.05 EPS, Q1 2026 earnings at $1.46 EPS and FY2026 earnings at $5.99 EPS.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.04). The company had revenue of $3.02 billion for the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm’s revenue was down 10.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.21 EPS.

A number of other analysts also recently issued reports on the company. Evercore ISI lifted their target price on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research report on Wednesday, February 28th. Piper Sandler boosted their price target on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. increased their price objective on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Jefferies Financial Group boosted their target price on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, March 6th. Finally, Barrington Research increased their price target on shares of Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $81.09.

Henry Schein Stock Down 1.2 %

Shares of Henry Schein stock opened at $67.78 on Friday. Henry Schein has a 52-week low of $60.01 and a 52-week high of $82.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. The business’s 50 day simple moving average is $73.46 and its 200 day simple moving average is $72.31. The firm has a market cap of $8.71 billion, a PE ratio of 21.52, a P/E/G ratio of 1.70 and a beta of 0.87.

Insider Transactions at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Hedge Funds Weigh In On Henry Schein

Several institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Pzena Investment Management LLC increased its stake in shares of Henry Schein by 22.2% in the first quarter. Pzena Investment Management LLC now owns 989,671 shares of the company’s stock valued at $74,740,000 after buying an additional 180,113 shares during the period. Banyan Capital Management Inc. acquired a new stake in Henry Schein during the 1st quarter valued at approximately $5,867,000. Central Pacific Bank Trust Division bought a new position in Henry Schein during the 1st quarter worth approximately $914,000. FORA Capital LLC bought a new position in Henry Schein during the 1st quarter worth approximately $1,816,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of Henry Schein by 11.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 12,869 shares of the company’s stock worth $972,000 after purchasing an additional 1,279 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.